Wednesday, November 1, 2017
Guest Post from Sandro Santagata, MD, PhD: Papillary Craniopharyngioma Trial
I am pleased to present a guest post from Dr. Sandro Santagata of Brigham and Women’s Hospital/Dana Farber Cancer Center, who writes:
Our group of collaborators has recently opened a Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas that is sponsored by the Alliance for Clinical Trials in Oncology.
The eligibility criteria are listed here: https://clinicaltrials.gov/ct2/show/NCT03224767
The trial is based on work published in these two papers:
I am happy to answer any questions that our colleagues may have about this trial. firstname.lastname@example.org